Interstitial lung disease in patients with anti-neutrophil c... : Current Opinion in Pulmonary
Medicine Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated …

Considerable variability exists in the way health-care providers treat patients with
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in Latin America. The most …

Background Since the publication of the EULAR recommendations for the management of
antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in 2016, several …

Objectives Severe infections contribute to morbidity and mortality in antineutrophil cytoplasm
antibody-associated vasculitis (AAV). This study aimed to identify risk factors associated with …

Large-and small-vessel vasculitis are complex potentially life-threatening systemic
autoimmune diseases that have recently been subjected to considerable immunologic and …

Antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are small-vessel
vasculitides that include granulomatosis with polyangiitis (formerly Wegener's …

Objective The objective of this study was to compare the efficacy and safety of two rituximab
(RTX) regimens for the induction of remission in severe antineutrophil cytoplasm antibody …

Abstract Objective In 2020, the Canadian Vasculitis Research Network (CanVasc) published
their updated recommendations for the management of ANCA-associated vasculitides …

Introduction Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but potentially
lethal systemic vasculitis. Only a few prospective therapeutic trials had been conducted in …

Background Antibiotic prophylaxis is recommended during ANCA-associated vasculitis
(AAV) induction. We aimed to describe the frequency, persistence, and factors associated …